Why the study?
The study was conducted to examine the possible beneficial effects of gallic acid against doxorubicin-induced cardiotoxicity in an experimental model.
Does gallic acid prevent doxorubicin-induced cardiotoxicity in an experimental rat model?
Does gallic acid prevent doxorubicin-induced cardiotoxicity in an experimental rat model?
Gallic acid shows potential as a cardioprotective agent against doxorubicin-induced cardiotoxicity by mitigating oxidative stress and inflammation in a preclinical model.
Answers are grounded in this paper and cite their sources.
Should not yet inform clinical use of gallic acid; leaves open translation from rat doxorubicin models.
The present study aims to examine the possible beneficial effects of gallic acid (GA) against doxorubicin-induced cardiotoxicity in the experimental model. Rats were weighed and divided into groups. Groups as following; control, gallic acid (GA), doxorubicin (DOX) and GA + DOX groups. At the end of the experiment, rats were sacrificed and heart tissue removed. The tissues were analysed in terms of biochemical (MDA, SOD, CAT, GSH, GPx), pathological (hyaline degeneration, Zenkerin necrosis, hyperaemia) and immunohistochemical (TNF-α, Cox-2). MDA level decreased and antioxidant enzyme activities increased in GA + DOX group compared to doxorubicin group. TNF-α, Cox-2 expression levels were severe in the DOX group. Also, pathologic tissue damage in heart tissue increased due to doxorubicin. Additionally, pathologic tissue damage and TNF-α, Cox-2 expression levels decreased in GA + DOX group. According to our findings, GA has protective effect against doxorubicin-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Akdemi̇r et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: